论文信息 - Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment - 字舞流文

Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

Stephanie J. Lee | G. Hill | P. Ordentlich | D. Weisdorf | B. Blazar | M. Arora | M. Jagasia | Aaron C. Schmitt | M. Meyers | M. Zaid | S. Sankoh | A. Stasi | C. Quaranto